Combination of breast imaging parameters obtained from ¹⁸F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer☆

Highlights: • For patients with a localized luminal/HER2 negative breast cancer, 18F-FDG PET-CT may predict the probability of breast conserving surgery. • Imaging data resulting from ¹⁸F-FDG PET-CT could help clinicians and breast cancer patients to optimize clinical decision-making. • The integration of imaging parameters such as total breast volume and delta metabolic tumor volume could improve the accuracy of nomograms. - Abstract: IntroductionThe luminal/Human Epidermal growth factor Receptor 2 (HER2) negative subtype of breast cancer has low chemo-sensitivity. When neoadjuvant chemotherapy (NAC) is indicated in this subtype, before a possible breast-conserving surgery (BCS), it is more reasonable to target tumor shrinkage than complete pathological tumor response. We aimed to identify breast and tumor ¹⁸Fluoro-deoxy-glucose (¹⁸F-FDG) PET-CT scan imaging features for the early prediction of BCS after NAC in luminal/HER2 negative subtypes of breast cancer.